Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
BB

BBHETF / FundVanEck Biotech ETF

$248.82 last close 2026-11-16
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment BBH's does — no target price to set, unlike a price alert.

Sharia status
NOT COMPLIANT
Screened by look-through to its filed holdings — 92% of portfolio weight covered
Fund look-through

VanEck Biotech ETF · VanEck ETF Trust

25 holdings

NON-COMPLIANT 13.78% of portfolio weight is in non-compliant holdings, over the 5% threshold.

25 holdings, 22 matched (92% of weight). Portfolio as of 2026-06-30, filed 2026-08-26. Source: SEC Form N-PORT.

2.28% of this portfolio’s income is non-permissible — weighted across holdings, computed over 87% of portfolio weight (21 of 25 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.

78.2% compliant 0.0% questionable 13.8% non-compliant 8.0% unscreened

All holdings (25)
HoldingStatusWeightEvery methodology, and the debt ratio behind it
AMGN Amgen Inc COMPLIANT 15.25% AAOIFI21.4% Usmani56.2% Dow Jones Islamic31.0% S&P Shariah32.5% MSCI Islamic56.2% MSCI Islamic M-Series32.5% FTSE Shariah56.2%
GILD Gilead Sciences Inc COMPLIANT 12.79% AAOIFI14.4% Usmani53.2% Dow Jones Islamic18.6% S&P Shariah21.4% MSCI Islamic53.2% MSCI Islamic M-Series21.4% FTSE Shariah53.2%
VRTX Vertex Pharmaceuticals Inc COMPLIANT 9.10% AAOIFI1.6% Usmani7.2% Dow Jones Islamic1.7% S&P Shariah1.7% MSCI Islamic7.2% MSCI Islamic M-Series1.7% FTSE Shariah0.0%
REGN Regeneron Pharmaceuticals Inc COMPLIANT 6.21% AAOIFI2.4% Usmani6.5% Dow Jones Islamic3.0% S&P Shariah2.7% MSCI Islamic4.8% MSCI Islamic M-Series2.7% FTSE Shariah4.8%
Revolution Medicines Inc UNSCREENED 5.27% no in-house ratios for this holding
ARGX Argenx SE COMPLIANT 4.97% AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah—
NTRA Natera Inc COMPLIANT 4.92% AAOIFI0.5% Usmani9.0% Dow Jones Islamic0.9% S&P Shariah1.2% MSCI Islamic9.0% MSCI Islamic M-Series1.2% FTSE Shariah3.0%
IQV IQVIA Holdings Inc NON_COMPLIANT 4.31% AAOIFI36.7% Usmani55.2% Dow Jones Islamic47.8% S&P Shariah44.8% MSCI Islamic54.4% MSCI Islamic M-Series44.8% FTSE Shariah53.4%
ALNY Alnylam Pharmaceuticals Inc COMPLIANT 3.83% AAOIFI1.1% Usmani3.1% Dow Jones Islamic0.6% S&P Shariah0.7% MSCI Islamic3.1% MSCI Islamic M-Series0.7% FTSE Shariah0.0%
BIIB Biogen Inc COMPLIANT 3.63% AAOIFI19.7% Usmani23.1% Dow Jones Islamic29.8% S&P Shariah27.2% MSCI Islamic23.1% MSCI Islamic M-Series27.2% FTSE Shariah22.7%
MRNA Moderna Inc NON_COMPLIANT 3.36% AAOIFI1.4% Usmani9.4% Dow Jones Islamic5.5% S&P Shariah4.5% MSCI Islamic9.2% MSCI Islamic M-Series4.5% FTSE Shariah4.4%
ILMN Illumina Inc COMPLIANT 3.17% AAOIFI1.6% Usmani8.1% Dow Jones Islamic2.7% S&P Shariah2.7% MSCI Islamic8.1% MSCI Islamic M-Series2.7% FTSE Shariah0.0%
UTHR United Therapeutics Corp NON_COMPLIANT 2.83% AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0%
ONC BeOne Medicines Ltd COMPLIANT 2.81% AAOIFI2.8% Usmani12.5% Dow Jones Islamic0.3% S&P Shariah0.3% MSCI Islamic12.5% MSCI Islamic M-Series0.3% FTSE Shariah11.7%
Insmed Inc UNSCREENED 2.67% no in-house ratios for this holding
INCY Incyte Corp COMPLIANT 2.49% AAOIFI0.1% Usmani0.7% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.3% MSCI Islamic M-Series0.1% FTSE Shariah0.0%
NBIX Neurocrine Biosciences Inc COMPLIANT 2.08% AAOIFI2.9% Usmani8.6% Dow Jones Islamic3.4% S&P Shariah3.5% MSCI Islamic8.6% MSCI Islamic M-Series3.5% FTSE Shariah0.0%
22UA.DE BioNTech SE NON_COMPLIANT 1.94% AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail
ICLR ICON PLC COMPLIANT 1.90% AAOIFI22.8% Usmani21.6% Dow Jones Islamic26.9% S&P Shariah20.7% MSCI Islamic21.6% MSCI Islamic M-Series20.7% FTSE Shariah20.8%
TECH Bio-Techne Corp COMPLIANT 1.54% AAOIFI4.2% Usmani18.4% Dow Jones Islamic5.1% S&P Shariah4.8% MSCI Islamic18.4% MSCI Islamic M-Series4.8% FTSE Shariah15.2%
CRL Charles River Laboratories International Inc COMPLIANT 1.50% AAOIFI17.7% Usmani38.3% Dow Jones Islamic30.3% S&P Shariah28.5% MSCI Islamic38.3% MSCI Islamic M-Series28.5% FTSE Shariah32.8%
BMRN BioMarin Pharmaceutical Inc NON_COMPLIANT 1.34% AAOIFI37.0% Usmani36.1% Dow Jones Islamic36.6% S&P Shariah32.3% MSCI Islamic36.1% MSCI Islamic M-Series32.3% FTSE Shariah36.1%
QGEN QIAGEN NV COMPLIANT 1.06% AAOIFI20.8% Usmani28.9% Dow Jones Islamic18.9% S&P Shariah18.9% MSCI Islamic28.9% MSCI Islamic M-Series18.9% FTSE Shariah26.3%
TEM Tempus AI Inc COMPLIANT 0.98% AAOIFI0.7% Usmani3.5% Dow Jones Islamic0.8% S&P Shariahpass MSCI Islamic3.5% MSCI Islamic M-Seriespass FTSE Shariah0.0%
State Street Global Advisors UNSCREENED 0.06% no in-house ratios for this holding

The published standards disagree about this fund by 46 points of portfolio weight — 59.3% of it passes S&P Shariah, 13.4% passes MSCI Islamic. Which number is yours depends on which standard you follow.

These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.

ratios pass on 58.0% ratios fail on 20.0% 22.1% not rated under AAOIFI

22 of 25 listed holdings carry our own per-methodology verdicts (92% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 20 (85% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.

Non-compliant holdingWeight
IQV IQVIA Holdings Inc 4.31%
MRNA Moderna Inc 3.36%
UTHR United Therapeutics Corp 2.83%
22UA.DE BioNTech SE 1.94%
BMRN BioMarin Pharmaceutical Inc 1.34%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure1 of 4 timeframes bullish · 58.8% aligned
VWAPPrice below VWAP ($255.38)
VolumeRelative volume 3.9× the 20-day average
Momentum10-day rate of change -2.2%

VanEck Biotech ETF (BBH) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.

Market & analysts
Momentum (10d)
-2.2%
rate of change
SMC grade
C · 58
58.8% aligned
C · 58
SMC grade — 58.8% timeframe alignment
-2.2%
Rate of change (10d)

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for BBH — this runs off the critical path so the page paints first. It will appear here on its own.

Tracked investors holding BBH
InvestorFirmPositionWeightAs of
Joel Greenblatt Gotham Asset Management $0M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

261.63241.20220.76200.33179.902025-11-172026-05-192026-11-16

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
248.49
S2
250.12
S1
251.42
PIVOT
253.05
R1
254.35
R2
255.98
R3
257.28

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
222.53 – 238.88
±3.54% from 230.70, made 2026-09-16 · resolves 2026-09-23
BUY
from 19 indicators
74.9% of our last 10571 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.2% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

BUY
19 indicators
OscillatorsSELL
2 buy · 2 neutral · 3 sell
Moving averagesBUY
7 buy · 0 neutral · 5 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)48.10NEUTRAL
Stochastic %K (14)13.71BUY
CCI (20)-51.16NEUTRAL
Williams %R (14)-86.29BUY
MACD (12,26,9)-1.02SELL
ROC (10)-2.23SELL
Momentum (10)-5.68SELL
EMA (10)253.75SELL
SMA (10)255.22SELL
EMA (20)252.09SELL
SMA (20)253.31SELL
EMA (30)249.69SELL
SMA (30)248.67BUY
EMA (50)244.53BUY
SMA (50)244.16BUY
EMA (100)232.76BUY
SMA (100)230.78BUY
EMA (200)216.16BUY
SMA (200)209.92BUY

About VanEck Biotech ETF

The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BULLISH 42
🕐 1H RANGING 43
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-2.2%
Rate of change (10d)
3.9×
Volume vs its 20-day average
2.80
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is a fund screened on its name?

No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.

What does unrated weight mean?

It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.

Does the issuer's board make it compliant?

It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.

How often is this re-screened?

When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.